Navigation Links
EntreMed Reports Fourth Quarter and Year-End 2011 Financial Results
Date:3/10/2012

ations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time.  Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed.

Actual results could differ materially from those currently anticipated due to a number of factors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; our history of losses and expectation of incurring continued losses; the risk that our stockholders may not approve our recent financing transaction and our ability to repay the indebtedness incurred in connection with issuance and sale of the convertible notes if such notes are not converted into shares of common stock; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility of our common stock; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidate; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; declines in actual sales of Thalomid® resulting in reduced royalty payments; risks associated with our product candidates; any early-stage products under development; results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; the lack of success in the clinical development of any of our products; dependence on third parties; and risks relating to the commercialization, if any, of our  proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); and our ability to comp
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients
2. EntreMed Reports Fourth Quarter and Year-End 2010 Financial Results
3. EntreMed Reports Receipt of Third Quarter Royalty Payment
4. EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
5. EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
6. EntreMed to Present at the New York Society of Security Analysts Industry Conference
7. EntreMeds MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
8. EntreMed Reports Third Quarter 2008 Financial Results
9. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
10. EntreMed to Present at BioPartnering Europe Conference
11. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... and Queens, New York (PRWEB) October 02, 2014 ... is pleased to announce funding received to investigate ... in Alzheimer’s disease. A grant award from the ... on Aging (NIA), National Institutes of Health (NIH) ... Novel AD Therapeutics." The company also received a ...
(Date:10/2/2014)... California (PRWEB) October 02, 2014 ... Livermore National Laboratory (LLNL) a grant today to ... researchers to better understand how the brain works ... project is part of NIH's efforts to support ... Neurotechnologies) Initiative, a new research effort to revolutionize ...
(Date:10/2/2014)... and BRIDGEWATER, N.J. , Oct. 2, ... a leader in synthetic biology, and Amneal ... manufacturer by volume in the U.S., today announced ... (ECC) for a target active pharmaceutical ingredient (API).  ... of the collaboration is to develop a consistent, ...
(Date:10/1/2014)... 1, 2014  Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" ... and sale of high pressure-based sample preparation systems to ... been invited to present at the 2 nd ... , Poland.  The Conference will take place at the ... Richard T. Schumacher , President and CEO of PBI, ...
Breaking Biology Technology:Gismo Therapeutics Inc. Awarded Grants to Develop New Alzheimer's Disease Therapeutics 2Gismo Therapeutics Inc. Awarded Grants to Develop New Alzheimer's Disease Therapeutics 3NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 2NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 3NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 4Intrexon and Amneal Expand Relationship with Second Product Collaboration 2Intrexon and Amneal Expand Relationship with Second Product Collaboration 3Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 2Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 3Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 4
... Genetics ,™ Inc., an innovative molecular diagnostics company developing the ... it completed the initial closing of a $14 million Series ... OrbiMed Advisors , Safeguard Scientifics, Inc. (NYSE: ... Proceeds from this financing will be used to augment commercial ...
... Want a see-through cellphone you can wrap around your wrist? ... Rice University chemist James Tour, whose lab has developed transparent, ... Tour revealed today in a talk at the national ... Diego that the new type of memory could combine with ...
... Centrix, a Nevada-based biotech corporation, announced this week its development ... a term used in programming wearable TheraEX (TM) skin ... field that surrounds all life forms. When ... in its basic form, it embodies seven major layers powered ...
Cached Biology Technology:Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team 2Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team 3Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team 4Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team 5AlphaBio Centrix, LLC Announces a New Discovery for Programming Energetic Patches 2
(Date:9/30/2014)... almost any aquatic environment on Earth, but when the ... pushed to the limit. The amount of time needed ... how different species cope in the future, reveals a ... published in the scientific journal Proceedings of the ... thanks to increasing levels of greenhouse gases in the ...
(Date:9/30/2014)... to know what goes wrong with your muscles because of ... what "normal" actually is. That,s where a new research report ... FASEB Journal comes in. In the report, a ... molecules that can help scientists "see" which genes are active ... found never-before-detected gene activity and that men have approximately 400 ...
(Date:9/30/2014)... (September 30, 2014) People who suffer from asthma ... to control their asthma besides properly taking medications and ... article in the Annals of Allergy, Asthma and ... of Allergy, Asthma and Immunology (ACAAI), asthma sufferers can ... lifestyle. The woman described in the Annals article improved ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Scientists identify which genes are active in muscles of men and women 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... requirements of new names for algae, fungi and plants ... Melbourne in July 2011 initiated several important challenges to scientists, ... the Congress decisions, the open access journal PhytoKeys ... one each day for the first week of 2012, starting ...
... This release is available in German . ... this more often when kin or mates are present than ... evidence that they take the other group members, knowledge state ... Anthropology in Leipzig, Germany, and the University of St. Andrews, ...
... found that elderly people with higher levels of several vitamins ... performance on mental acuity tests and less of the brain ... produced just the opposite result. The study was among ... range of blood nutrient levels instead of basing findings on ...
Cached Biology News:Brave new world 2Brave new world 3I know something you don't know -- and I will tell you! 2Diet, nutrient levels linked to cognitive ability, brain shrinkage 2
Troponin I (22B11)...
Microlite 1+ 1x12 Strip assembled, flat bottom; the ideal vessel for low signal luminescent reactions, offering medium binding with enhanced dynamic range, extra high reflectivity and minimal cross t...
Immulon 4 HBX 1x12 Strip, flat bottom; high binding extra surface with special resin and irradiation, offers maximum protein uptake....
... regulator and pressurized syringe holder for any researcher ... flow rate Microinjecting Fine microliter delivery ... added to any new or existing perfusion rig ... homemade. Connect to house air or a compressor ...
Biology Products: